Table 4.
Model outcomes and costs (€) at the end of a life-long simulation (average values per patient)
| Strategy | Exacerbation number | Symptom-free days | Direct cost | Indirect cost | Direct + Indirect cost |
|---|---|---|---|---|---|
| C | 12.04 | 0 | 34,632.09 | 715.74 | 35,347.83 |
| S | 10.07 | 55 | 33,369.28 | 619.87 | 33,989.15 |
| F | 10.14 | 37 | 34,754.38 | 623.55 | 35,377.93 |
| SF | 9.09 | 257 | 34,037.71 | 571.93 | 34,609.64 |
| FB | 9.66 | 220 | 33,944.51 | 599.73 | 34,544.25 |
Abbreviations: C, control; F, fluticasone alone; FB, formoterol/budesonide; S, salmeterol alone; SF, salmeterol/fluticasone.